Neurocrine Biosciences, Inc.

NasdaqGS:NBIX Voorraadrapport

Marktkapitalisatie: US$17.5b

Neurocrine Biosciences Toekomstige groei

Future criteriumcontroles 4/6

Neurocrine Biosciences zal naar verwachting groeien in winst en omzet met respectievelijk 24.2% en 12% per jaar. De winst per aandeel zal naar verwachting groeien met 22.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 20.9% zijn.

Belangrijke informatie

24.2%

Groei van de winst

22.61%

Groei van de winst per aandeel

Biotechs winstgroei25.2%
Inkomstengroei12.0%
Toekomstig rendement op eigen vermogen20.95%
Dekking van analisten

Good

Laatst bijgewerkt07 Jul 2026

Recente toekomstige groei-updates

Analyseartikel • May 08

Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next

Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) investors will be delighted, with the company turning in some strong...

Recent updates

Seeking Alpha • Jul 02

Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno

Summary Neurocrine Biosciences, Inc. remains a Buy, driven by robust growth from Ingrezza, Crenessity, and the recent Vykat acquisition. Q1 2026 revenues rose 44% year-on-year to $811m, with Ingrezza and Crenessity annualizing at blockbuster levels and Vykat showing rapid ramp-up. NBIX stock valuation reflects high-growth expectations; forward P/S ~5.1x and P/E ~30x, justified by an expanding commercial portfolio and pipeline catalysts. Patent protection through 2038 for Ingrezza and solid balance sheet support long-term growth, with pipeline approvals offering further upside potential. Read the full article on Seeking Alpha
Narratiefupdate • Jun 24

NBIX: Future Upside Will Rely On Expanding Rare Disease Franchise

Analysts have nudged their price target for Neurocrine Biosciences higher to $243.06 from $241.76, citing updated views on revenue growth, profit margins, and future P/E expectations following recent coverage initiations and the addition of Soleno Therapeutics' Vykat XR to the portfolio. Analyst Commentary Recent Street research on Neurocrine Biosciences highlights a generally constructive tone, with several firms updating views on the stock following the completion of the Soleno Therapeutics acquisition and fresh coverage initiations.
Analyseartikel • Jun 19

Neurocrine Biosciences (NBIX) Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data

Neurocrine Biosciences (NBIX) is in focus after new CRENESSITY data at ENDO 2026 highlighted hormone normalization in classic CAH due to 11ß hydroxylase deficiency, alongside two-year cardiometabolic and bone health outcomes in adults. See our latest analysis for Neurocrine Biosciences. At a share price of $158.29, Neurocrine Biosciences has given investors a 23.97% 90 day share price return and a 25.08% 1 year total shareholder return, pointing to momentum that has built alongside ENDO 2026...
Narratiefupdate • Jun 09

NBIX: Future Upside Will Depend On Rare Disease Portfolio Execution

Analysts have lifted the fair value estimate for Neurocrine Biosciences by about $6 to $192.88, reflecting updated views on revenue growth, profitability and valuation after the Soleno acquisition, along with recent Street research highlighting a long runway for key drugs and additional contributions from Vykat XR. Analyst Commentary Recent Street research around Neurocrine Biosciences has been broadly constructive, with several firms updating models after the Soleno acquisition and new readthroughs on key products.
Narratiefupdate • May 26

NBIX: Pipeline Execution And Integration Risks Will Shape Balanced Future Returns

Analysts lifted their fair value target for Neurocrine Biosciences by about $3 to $144, citing updated assumptions for revenue growth of 14.83%, a profit margin of 18.43%, and a recalibrated future P/E of 21.28x that reflects confidence in the long runway of its key approved drugs and potential contributions from Crenessity and osavampator. Analyst Commentary Recent Street research on Neurocrine Biosciences highlights a mix of optimism around the company’s approved therapies and emerging pipeline, alongside selective caution on execution and valuation.
Analyseartikel • May 08

Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next

Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) investors will be delighted, with the company turning in some strong...
Narratiefupdate • May 07

NBIX: Future Upside Will Depend On Execution Across Two Core Franchises

The updated analyst price target for Neurocrine Biosciences moves to $241.76 from $203.91, with analysts pointing to higher modeled revenue growth and slightly richer future P/E assumptions, partly balanced by a modestly lower profit margin outlook and a small change in the discount rate. Analyst Commentary Recent Street research on Neurocrine Biosciences shows a cluster of price target changes and fresh coverage that tilt bullish overall, even with a few modest trims.
Narratiefupdate • Apr 21

NBIX: Future Upside Will Hinge On Tardive Dyskinesia Franchise Execution

The updated analyst price target for Neurocrine Biosciences increases to $186.45 from $178.04. Analysts attribute the change to more supportive long-term earnings expectations and higher assumed future P/E multiples, even as they refine revenue growth and margin assumptions.
Narratiefupdate • Apr 07

NBIX: Mixed 2026 Guidance And Policy Risks Will Shape Future Returns

Analysts have made a small upward adjustment to the fair value estimate for Neurocrine Biosciences to about $140.54, reflecting updated price targets that weigh mixed revisions across the Street against generally constructive views on Ingrezza and Crenessity. Analyst Commentary Street research around Neurocrine Biosciences has been active, with a mix of supportive views on key assets like Ingrezza and Crenessity and a series of price target tweaks that pull in different directions.
Narratiefupdate • Mar 24

NBIX: Future Upside Will Depend On Crenessity Adoption And Pipeline Progress

Analysts have trimmed the blended price target for Neurocrine Biosciences slightly to about $178, reflecting modest tweaks to growth, discount rate and P/E assumptions, while incorporating mixed but generally constructive views on Ingrezza and Crenessity uptake from recent research updates. Analyst Commentary Street research on Neurocrine Biosciences has been active, with several firms adjusting price targets and models around recent earnings, updated guidance and new information on Ingrezza and Crenessity.
Narratiefupdate • Mar 09

NBIX: 2026 Guidance Execution And CAH Competition Will Shape Future Returns

Analysts have kept the fair value estimate for Neurocrine Biosciences steady at $140, while revising their models slightly to reflect updated revenue growth, margins, and P/E assumptions following recent earnings, guidance, and a mix of modest price target cuts and a fresh $160 Outperform initiation. Analyst Commentary Across recent research, you are seeing a mix of optimism around the pipeline and commercial assets along with a cluster of more cautious valuation resets.
Narratiefupdate • Feb 23

NBIX: Execution On 2026 Guidance And Competitive CAH Data Will Shape Outlook

Neurocrine Biosciences' updated analyst price target of $140.00, down from $169.00, reflects refreshed models after Q4 results and 2026 guidance, with analysts still pointing to Ingrezza and Crenessity as key drivers in their long term assumptions despite recent target trims across the Street. Analyst Commentary Street research around Neurocrine Biosciences has turned more mixed, with several bearish analysts trimming price targets following Q4 results and updated 2026 guidance, while a few others have made only modest upward adjustments.
Narratiefupdate • Feb 09

NBIX: Future Returns Will Hinge On Crenessity Execution And Pipeline Delivery

Analysts made a modest trim to their Neurocrine Biosciences price targets, generally landing around the high US$170s. Updated models reflect slightly more conservative revenue growth assumptions and a marginally higher discount rate, partly offset by steady margin expectations and supportive views on Crenessity and Ingrezza.
Narratiefupdate • Jan 24

NBIX: Future Revenue Will Depend On Execution Across Two Key Franchises

Analysts have raised their fair value estimate for Neurocrine Biosciences to about US$204 from US$192. This reflects updated assumptions that include slightly stronger revenue growth, higher profit margins and a lower future P/E multiple after recent Street research refined expectations for Ingrezza, Crenessity and competitor dynamics.
Narratiefupdate • Jan 10

NBIX: Commercial Execution And Pipeline Progress Will Drive Future Shareholder Returns

Analysts have raised their fair value estimate for Neurocrine Biosciences from about $177.92 to $179.66, reflecting updated models that incorporate recent price target revisions, current product performance, and expectations regarding future competition and commercial execution. Analyst Commentary Recent research updates show a mix of optimism and caution around Neurocrine Biosciences, with most price target moves clustering around the high $160s to mid $180s and reflecting updated models on current products, competitive developments in congenital adrenal hyperplasia, and spending to support commercial execution.
Narratiefupdate • Dec 17

NBIX: Advancing CNS Pipeline Readouts Will Drive Future Shareholder Returns

Analysts have modestly increased their average price target for Neurocrine Biosciences by about $3, to roughly $178, citing stronger than expected product performance, sustained Ingrezza growth momentum, and growing confidence in the company’s advancing pipeline despite potential IRA related pricing headwinds. Analyst Commentary Street research remains broadly constructive on Neurocrine, with multiple firms nudging price targets higher as they factor in stronger execution, commercial visibility for Ingrezza and Crenessity, and a maturing late stage pipeline.
Narratiefupdate • Dec 03

NBIX: Late-Stage CNS Pipeline Readouts Will Drive Future Shareholder Value

Analysts have nudged their blended price target for Neurocrine Biosciences modestly higher to the high $170s to low $180s range, reflecting stronger than expected Ingrezza and Crenessity performance, confidence in commercial execution ahead of IRA related headwinds, and growing optimism around the longer term pipeline. Analyst Commentary Bullish analysts largely frame the recent pullback as a mismatch between robust fundamentals and short term market sentiment, with multiple firms lifting price targets into the mid $160s to mid $190s range even as shares consolidated.
Narratiefupdate • Nov 19

NBIX: Late-Stage Pipeline Advancements Will Drive Shareholder Value Amid Industry Headwinds

Neurocrine Biosciences' analyst price target has increased modestly, up by $3 to $174. Analysts cite ongoing strong commercial performance, expanded sales force initiatives, and a robust late-stage pipeline as supporting factors for sustained growth potential.
Narratiefupdate • Nov 05

NBIX: Expanding Commercial Momentum And Pipeline Advances Will Drive Shareholder Value

The analyst price target for Neurocrine Biosciences has been raised from approximately $170 to $175 per share. This reflects analyst optimism about the company’s strong recent earnings, expanded sales efforts, and ongoing commercial and pipeline momentum.
Narratiefupdate • Oct 22

Analysts Boost Neurocrine Biosciences Price Target Citing Strong Revenue Outlook and Clinical Results

Analysts have raised their price target for Neurocrine Biosciences from $168.25 to $169.95. They cite stronger revenue outlooks for key products and supportive recent clinical trial data as the main reasons for this adjustment.
Seeking Alpha • Apr 22

Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025

Summary Company's valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in 2025, targeting patients unresponsive to antipsychotics. The company also anticipates phase 3 data for valbenazine in treating dyskinetic cerebral palsy in 2025, presenting another market opportunity. Neurocrine's financial health is robust, with $1.8 billion in cash and strong revenue growth from INGREZZA, which saw a 23% year-over-year increase in Q4 2024. The Schizophrenia market across the 7 major markets is expected to reach $17 billion by 2031. Read the full article on Seeking Alpha

Winst- en omzetgroeiprognoses

NasdaqGS:NBIX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20285,0131,4191,8001,86417
12/31/20274,4731,0941,3781,42420
12/31/20263,77453090969321
3/31/20263,102669831864N/A
12/31/20252,861479749783N/A
9/30/20252,683428593637N/A
6/30/20252,510348529567N/A
3/31/20252,413306492530N/A
12/31/20242,355341557595N/A
9/30/20242,243386440476N/A
6/30/20242,120339495530N/A
3/31/20241,982370614645N/A
12/31/20231,887250362390N/A
9/30/20231,784191385409N/A
6/30/20231,673176281296N/A
3/31/20231,59964237255N/A
12/31/20221,489155323339N/A
9/30/20221,38958177201N/A
6/30/20221,29712133164N/A
3/31/20221,20871102129N/A
12/31/20211,13490233257N/A
9/30/20211,069445328347N/A
6/30/20211,032365251265N/A
3/31/20211,045402266280N/A
12/31/20201,046407218229N/A
9/30/20201,04293222232N/A
6/30/20201,006205337350N/A
3/31/2020887177283295N/A
12/31/201978837N/A147N/A
9/30/201967521N/A100N/A
6/30/201960518N/A71N/A
3/31/2019519-39N/A27N/A
12/31/201845121N/A101N/A
9/30/201841410N/A91N/A
6/30/2018323-52N/A13N/A
3/31/2018233-106N/A-55N/A
12/31/2017162-143N/A-94N/A
9/30/201767-194N/A-167N/A
6/30/20176-220N/A-188N/A
3/31/2017N/A-200N/A-154N/A
12/31/201615-141N/A-106N/A
9/30/201615-126N/A-90N/A
6/30/201615-123N/A-77N/A
3/31/201615-107N/A-49N/A
12/31/201520-89N/A-38N/A
9/30/201520-79N/A-38N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei NBIX ( 24.2% per jaar) ligt boven de spaarquote ( 3.5% ).

Winst versus markt: De winst van NBIX ( 24.2% per jaar) zal naar verwachting sneller groeien dan de US markt ( 18.4% per jaar).

Hoge groeiwinsten: De winst van NBIX zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van NBIX ( 12% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 12.8% per jaar).

Hoge groei-inkomsten: De omzet van NBIX ( 12% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen NBIX zal naar verwachting over 3 jaar hoog zijn ( 20.9 %)

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/07/07 21:12
Aandelenkoers aan het einde van de dag2026/07/07 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Neurocrine Biosciences, Inc. wordt gevolgd door 39 analisten. 21 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Martha FreitagArgus Research Company
Brian SkorneyBaird
Aydin HuseynovBenchmark Company